Trial Profile
Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms AtTEnd; AtTEnd/ENGOT-en7
- 11 Mar 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Jan 2025.
- 24 Oct 2023 Primary endpoint has been met. (PFS in the MSI [ Time Frame: Up to 18 months after the last patient enrolled ]) , according to Results presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Primary endpoint has been met. (PFS [ Time Frame: Up to 18 months after the last patient enrolled ]PFS is defined as the time from randomization to the date of first progression or death from any cause, whichever comes first.) , according to Results presented at the 48th European Society for Medical Oncology Congress